The broad signaling effects of DGKα inhibition, as well as preferential activity against the treatment-resistant mesenchymal phenotype in GBM and other cancers, could translate to a host of promising anti-GBM combinations with a DGKα inhibitor. The gene discussed is DGKA; the disease is cancer.